Intellia to report Phase 3 CRISPR gene editing trial data April 27
Intellia Therapeutics Inc. (NASDAQ: NTLA) will report topline data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)